Search results for "Cytopenia"

showing 10 items of 123 documents

Fever of Unclear Origin and Cytopenia Because of Acute Splenic Sequestration in a Young Immunocompetent Carrier of Beta-Globin Mutation for Hb Vallet…

2008

Fever of unclear origin is a clinical challenge in medical practice. Infectious diseases, neoplasms, and collagen vascular illnesses are its main causes in adults and children. Acute splenic sequestration crises, a known potentially fatal complication of sickle cell disease and sickle beta-thalassemia, are uncommon in beta-heterozygosis. We describe a case of prolonged recurrent episodes of fever with spontaneous resolution, commencing at age 10 in a 15-year-old boy with a history of hypochromic microcytic anemia attributed to a thalassemic trait. He was admitted twice to our university hospital for continuous-remittent fever with a pruritic, macular evanescent Still's skin rash, severe spl…

AdultMaleAdolescentFeverAnemiaHemoglobins AbnormalThalassemiaHepatosplenomegalybeta-Globinshemic and lymphatic diseasesmedicineHumansChildCytopeniabusiness.industryBeta thalassemiaAnemiaGeneral Medicinemedicine.diseaseHematologic DiseasesHypochromic microcytic anemiaHemoglobinopathyMutationImmunologymedicine.symptomSplenic diseasebusinessImmunocompetenceSpleenThe American Journal of the Medical Sciences
researchProduct

Pulmonary infiltrate with characteristic “reversed halo” and “air crescent” signs

2016

Male0301 basic medicinePathologymedicine.medical_specialtyAntifungal AgentsPancytopenia030106 microbiologyAstrocytoma030218 nuclear medicine & medical imagingImmunocompromised Host03 medical and health sciences0302 clinical medicineBronchoscopyInternal MedicineHumansMedicineInvasive Pulmonary Aspergillosisbusiness.industryMiddle AgedCombined Modality TherapyAspergillusPulmonary infiltratesVoriconazoleHaloTomography X-Ray Computedbusiness
researchProduct

Post-mortem findings in vaccine-induced thrombotic thrombocytopenia

2021

Greinacher et al.1 and Schultz et al.2 were the first to independently report the main clinical and laboratory features of 11 and five respective patients from Germany, Austria and Norway who developed life-threatening thrombohemorrhagic complications 5 to 16 days after the administration of the first dose of the chimpanzee adenoviral vector vaccine ChAdOx1nCoV-19 against SARS-CoV-2 and COVID-19. Subsequently Scully et al.3 reported similar findings in 23 patients treated with the same vaccine in the United Kingdom. More recently, See et al.4 reported a case series of 12 patients from the USA with cerebral venous sinus thrombosis following the vaccination with Ad26.CoV2.S employing a human …

Vaccinesmedicine.medical_specialtybusiness.industrySARS-CoV-2thrombotic thombocytopeniavaccine ChAdOx1nCoV-19MEDLINECOVID-19ThrombosisAutopsyCase ReportHematologymedicine.diseaseThrombosisAntiviral AgentsInternal medicineMedicineHumansAutopsybusinessPandemicsHaematologica
researchProduct

Doubtful association between TAR syndrome and increased nuchal translucency in the first trimester of pregnancy

2006

Gynecologymedicine.medical_specialtyPregnancybusiness.industryTAR syndromeObstetrics and GynecologySyndromemedicine.diseaseThrombocytopeniaUltrasonography PrenatalPregnancy Trimester FirstRadiusFirst trimesterPregnancymedicineHumansFemaleNuchal Translucency MeasurementbusinessIncreased nuchal translucencyGenetics (clinical)Prenatal Diagnosis
researchProduct

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.

2007

BACKGROUND. Clonal cytogenetic abnormalities (CCA) were detected in Philadelphia chromosome (Ph)-negative cells in some patients with chronic myeloid leukemia (CML) who attained a cytogenetic response to imatinib mesylate. In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells. METHODS. The authors compared the pretherapeutic risk factors (Kruskall-Wallis test), exposure to cytotoxic drugs (chi-square test), and overall and progression-free survival (Kaplan-Meyer and logistic regression analysis, respectively) of 515 patients with mostly chronic-…

OncologyMaleCancer ResearchMyeloidKaplan-Meier EstimatePiperazineshemic and lymphatic diseasesTreatment FailureAged 80 and overMyeloid leukemiaMiddle AgedPrognosisLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyBenzamidesCytogenetic AnalysisImatinib MesylateFemalemedicine.drugAdultmedicine.medical_specialtyNeutropeniaAntineoplastic AgentsPhiladelphia chromosomeDisease-Free SurvivalLeukemia Myeloid Chronic Atypical BCR-ABL Negativechronic myeloid leukemiaInternal medicineparasitic diseasesmedicineHumansAgedChromosome AberrationsChi-Square Distributionbusiness.industryMyelodysplastic syndromesCancerInterferon-alphaImatinibmedicine.diseaseThrombocytopeniaImatinib mesylateLogistic ModelsPyrimidinesMyelodysplastic SyndromesChronic DiseaseCancer researchbusinessFollow-Up StudiesCancer
researchProduct

Griscelli-Syndrom: ein Fallbericht

2003

Background: Griscelli syndrome is a rare disorder with poor prognosis. It is characterized by silver-grey hair or strands of silver-grey hair in childhood, and variable cellular immunodeficiency. The course of the untreated disease is fatal. Recurrent episodes of fever and lymphohistocytic infiltration of organs lead to hepatosplenomegaly, lymphadenopathy, pancytopenia, and progressive neurological impairment. Prognosis on morbidity and lethality depends on an early diagnosis. Patient: The girl we report on suffers from Griscelli syndrome. She developed normally and only her grey strands of hair, grey eyebrows, and eyelids were conspicuous. With the age of 4 years she presented with a first…

First episodemedicine.medical_specialtybusiness.industryHepatosplenomegalyDiseasemedicine.diseasePancytopeniaDermatologySurgeryEl NiñoImmunopathologyPediatrics Perinatology and Child HealthMedicinemedicine.symptombusinessGriscelli syndromeNeurological impairmentKlinische Pädiatrie
researchProduct

Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancer—An Extended Phase I MARGIT and AIO Trial

2008

Purpose Adjuvant 5-fluorouracil–based chemoradiotherapy has been shown to improve the prognosis of gastric cancer. To optimize these results, in the present study oxaliplatin and capecitabine were used instead of 5-fluorouracil. We sought to determine the maximum tolerated dose and the dose-limiting toxicities (DLT) of these drugs in combination with intensity-modulated radiotherapy. Methods and Materials Patients with resected adenocarcinoma of the stomach or the gastroesophageal junction were included. They received two cycles of induction chemotherapy (oxaliplatin and capecitabine [XelOx] regimen). Using standard Phase I methodology, patients received 45 Gy in 1.8-Gy fractions either in …

MaleOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsNauseamedicine.medical_treatmentDeoxycytidineGastroenterologyCapecitabineLeukocytopeniaStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingCapecitabineAgedChemotherapyRadiationbusiness.industryInduction chemotherapyMiddle AgedCombined Modality TherapyOxaliplatinOxaliplatinRegimenOncologyFemaleRadiotherapy AdjuvantFluorouracilmedicine.symptombusinessChemoradiotherapymedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus

2015

Abstract: The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a revie…

cancer patientpathogenesipositron emission tomographyhealthcare associated infectionSettore MED/06 - Oncologia Medicapatient monitoringradiodiagnosimedicine.medical_treatmentChemotherapy; Head and neck cancer; Radiotherapy; SepsisthrombocytopeniaReviewblood cultureorgan injurymedical terminologyMedicineHead and neck cancermetabolic acidosiC reactive proteinHead and Neck Neoplasmmedical specialisttreatment withdrawalconsensus developmentHematologyclinical practicesystemic inflammatory response syndromeItalyOncologyHead and Neck Neoplasmslaboratory testthrombocytosichemically induced/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingchemotherapy; head and neck cancer; radiotherapy; sepsis; oncology; hematology; geriatrics and gerontologyorgan perfusionhospitalizationHumansepsis Head and Neck Neoplasmmedicine.medical_specialtySettore MED/17 - Malattie InfettiveSepsibacterium culturediagnostic approach routefluorodeoxyglucosecancer chemotherapySepsisSDG 3 - Good Health and Well-beingSepsiscancer radiotherapyfollow upChemotherapyHumansinfection riskIntensive care medicineprocalcitonin antimicrobial therapyChemotherapyRadiotherapybusiness.industrydisease predispositionHead and neck cancerlactic acidChemotherapy; Head and neck cancer; Radiotherapy; Sepsis; Humans; Italy; Head and Neck Neoplasms; Sepsis; Hematology; Oncology; Geriatrics and Gerontologymedicine.diseasemortalityDelphi studyRadiation therapyinflammationincidencehyperglycemiaHuman medicineGeriatrics and Gerontologybusiness
researchProduct

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

2009

Abstract Abstract 2898 Poster Board II-874 Introduction: Panobinostat (LBH589) is a potent pan-deacetylase inhibitor (DACi) targeting epigenetic and non-epigenetic oncogenic pathways. Panobinostat is currently under clinical investigation in a variety of solid tumors and hematologic malignancies. A Phase IA/II trial evaluating oral panobinostat in patients (pts) with advanced hematologic malignancies is currently ongoing, and encouraging clinical activity has been reported previously in pts with lymphoma, myeloma, or leukemia. Here, preliminary activity of oral panobinostat in pts with myelofibrosis (MF) is described. Patients and methods: Pts with advanced hematologic malignancies were tre…

Oncologymedicine.medical_specialtyCytopeniaChemotherapybusiness.industrymedicine.medical_treatmentImmunologyChronic myelomonocytic leukemiaCell BiologyHematologyHematopoietic stem cell transplantationNeutropeniamedicine.diseaseBiochemistryChemotherapy regimenSurgeryTransplantationchemistry.chemical_compoundchemistryInternal medicinePanobinostatmedicinebusinessBlood
researchProduct

Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.

2009

Abstract Background/aim To present clinical and genetic characteristics of all Romanian patients with Gaucher disease type 1, in whom specific diagnosis has been confirmed by enzymatic and molecular methods and to analyze their outcome with and without enzymatic replacement therapy (ERT). Patients, methods There are fifty patients (F/M — 1.63/1) with Gaucher disease type 1. Clinical status, haemoglobin, thrombocytes, hepatic/splenic volume, bone mineral density and severity score were assessed at baseline and every six months thereafter. Thirty-nine patients (78%) received imiglucerase (44.4 ± 13.6 U/kg/2 weeks) for 3.1 +/− 1.4 years. Results Based on general prevalence data, our group repr…

AdultMalemedicine.medical_specialtyEvery Six MonthsBone diseaseImigluceraseAdolescentGenotypeDiseaseGastroenterologyYoung AdultInternal medicineGenotypeInternal MedicinemedicineHumansPlateletAge of OnsetChildAllelesBone mineralGaucher Diseasebusiness.industryRomaniaInfantAnemiaMiddle Agedmedicine.diseasePrognosisThrombocytopeniaSurgeryHexosaminidasesChild PreschoolMutationSplenomegalyGlucosylceramidaseFemalebusinessVisceromegalymedicine.drugEuropean journal of internal medicine
researchProduct